What is the success rate of stem cell therapy for Scleroderma (Systemic Sclerosis)?
There is no single success rate for cell-based treatment of systemic sclerosis. Autologous HSCT and investigational MSC infusion must be evaluated separately, and skin, lung, event-free survival and treatment-related mortality are different endpoints. Eligibility and risk depend on disease stage and organ involvement. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
What the evidence shows for Scleroderma (Systemic Sclerosis)
Randomised evidence and specialist recommendations support considering autologous HSCT for carefully selected severe early diffuse disease, while recognising substantial treatment-related risk. That evidence cannot be transferred to placental MSC infusion: the products, conditioning, mechanism, risks and endpoints are fundamentally different. MSC studies remain early and heterogeneous. No combined response rate is published here. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
Am I a candidate? → · Scleroderma (Systemic Sclerosis): full overview → · Scleroderma (Systemic Sclerosis) cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Scleroderma (Systemic Sclerosis): cell-therapy evidence and registered trials
- How much does stem cell therapy for Scleroderma (Systemic Sclerosis) cost? (2026)
- Scleroderma (Systemic Sclerosis) stem cell therapy — your questions answered (2026)
- Scleroderma (Systemic Sclerosis): cell-therapy evidence by therapy class
- MSC vs HSCT for Scleroderma (Systemic Sclerosis): what the registries show